{"id":"W4416387692","doi":"10.1016/j.annonc.2025.09.056","title":"LBA44 Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: Final overall survival from DUO-O/ENGOT-ov46/GOG-3025","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Defence and Security Accelerator; Humanitas University; Institute of Cancer Research; Yonsei University; University of Pittsburgh; Knight Cancer Institute, Oregon Health and Science University; Oregon Health and Science University; Università degli Studi di Milano; Debreceni Egyetem; AstraZeneca","keywords":"Bevacizumab; Durvalumab; Olaparib; Overall survival; Epithelial ovarian cancer; Survival analysis","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004388742,0.0002730273,0.0008079943,0.0001514423,0.0001669591,0.0004630664,0.0002719261,0.0002871006,0.001407168],"category_scores_gemma":[0.0005237008,0.000126353,0.0007287108,0.0002196554,0.0001543203,0.0003940125,0.0001760906,0.0009060386,0.0001817517],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006589841,"about_ca_system_score_gemma":0.0007447053,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001823256,"about_ca_topic_score_gemma":0.008173796,"domain_scores_codex":[0.9998536,0.00004206255,0.000009473244,0.00003372345,0.00001420622,0.00004698014],"domain_scores_gemma":[0.9998209,0.0000364105,0.00003417685,0.00001296304,0.00000602462,0.00008942544],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.366154,0.007401654,0.1125048,0.0008403177,0.003015907,0.0009229032,0.0002906382,0.00538181,0.01397298,0.0006423619,0.01007509,0.4787976],"study_design_scores_gemma":[0.08999409,0.2346926,0.6352931,0.0003275031,0.004533917,0.002808367,0.0003526419,0.008686552,0.004480014,0.00131429,0.01743213,0.00008477874],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906902,0.006432962,0.0001418475,0.0003614554,0.00009551345,0.0000767721,0.0004342829,0.00002563414,0.001741354],"genre_scores_gemma":[0.9961041,0.00178271,0.0002383266,0.0002414261,0.0000600027,0.00004611913,0.0007738668,0.000005408494,0.0007481445],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001823256,"threshold_uncertainty_score":0.004781306,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02589842150675203,"score_gpt":0.3407779570062561,"score_spread":0.3148795354995041,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}